LATEST SGEN NEWS
02.28.14 | 16:18 EST SEATTLE GENETICS INC /WA Files SEC form 10-K, Annual Report 02.28.14 | 14:17 EST Seattle Genetics Presents Data on Adcetris 02.27.14 | 10:53 EST Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Clinical Data at the 2014 Bone Marrow Transplant Tandem Meetings 02.27.14 | 09:58 EST 9:03 am Seattle Genetics highlights ADCETRIS (Brentuximab Vedotin) clinical data that demonstrate 92% objective response rate in ongoing Phase 1/2 cli 02.27.14 | 09:00 EST Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Clinical Data at the 2014 Bone Marrow Transplant Tandem Meetings 02.25.14 | 11:30 EST Insider Trading Alert - RKUS, POWI And SGEN Traded By Insiders 02.20.14 | 16:40 EST Seattle Genetics Moves Up In Market Cap Rank, Passing DENTSPLY International 02.15.14 | 09:32 EST What You Need to Know About Seattle Genetics Biggest Growth Driver 02.12.14 | 13:59 EST Why Seattle Genetics, Inc. Shares Soared 02.12.14 | 12:27 EST On The Fly: Midday Wrap
02.12.14 | 11:54 EST Why Seattle Genetics (SGEN) Hit An All-Time High Today 02.12.14 | 11:04 EST Jim Cramers 6 Stocks in 60 Seconds: BUD S LNG VJET SGEN CROX 02.12.14 | 09:54 EST [video] Cramers Six in 60: BUD, VJET, SGEN & more 02.12.14 | 08:50 EST Narrower-than-Expected Loss at Seattle Genetics 02.12.14 | 07:50 EST Seattle Genetics upgraded to Buy from Hold at Needham 02.12.14 | 02:15 EST Seattle Genetics Reports Fourth Quarter and Year 2013 Financial Results 02.11.14 | 19:20 EST Seattle Genetics CEO Discusses Q4 2013 Results - Earnings Call Transcript 02.11.14 | 17:32 EST Seattle Genetics Loss Widens Despite Higher Adcetris Sales 02.11.14 | 16:56 EST 4:12 pm Seattle Genetics beats by $0.11, beats on revs; Data anticipated in 2014 from ADCETRIS Phase 3 AETHERA trial and SGN-CD19A and SGN-CD33A pipel 02.11.14 | 16:25 EST Q4 2013 Seattle Genetics Inc Earnings Conference call (Webcast)
SGEN News: Seattle Genetics Presents Data from Novel Antibody-Drug Conjugate (ADC) SGN-CD19A at ASH 2013
Description: [Business Wire] - Seattle Genetics, Inc. today presented interim phase 1 clinical data from SGN-CD19A, an antibody-drug conjugate in development for the treatment of B-cell malignancies, including acute lymphoblastic leukemia , at the 55th American Society of Hematology Annual Meeting and Exposition taking place in New Orleans, Louisiana, December 7-10, 2013....
Get here more SGEN News: